In a major milestone for bladder cancer treatment, the U.S. Food and Drug Administration (FDA) has granted approval to Zusduri, a non-surgical gel-based therapy designed to treat patients with non–muscle-invasive bladder cancer (NMIBC). Developed by biotech company UroGen, Zusduri promises to reduce the need for repeat surgeries by offering an outpatient alternative that delivers chemotherapy directly into the bladder.
This approval marks a paradigm shift in how early-stage bladder cancer may be managed in the United States, offering a new level of convenience, comfort, and clinical effectiveness for patients.
A Breakthrough for Recurring Bladder Cancer
Bladder cancer is the sixth most common cancer in the U.S., affecting tens of thousands of patients annually. Among them, a large proportion suffers from low-grade, non–muscle-invasive tumors. These tumors do not invade the bladder wall but are highly prone to recurrence, leading to a cycle of repeated surgeries and monitoring.
Until now, the standard of care for such cases has largely been surgical removal through a procedure called transurethral resection of bladder tumor (TURBT). Patients often endure multiple TURBTs over their lifetime, each requiring anesthesia and carrying the risk of complications.
Zusduri offers a new option. As a chemo-hydrogel, the therapy is inserted via catheter and remains in the bladder for several hours, releasing the active agent over time. The idea is to provide direct and sustained exposure to the cancer cells, increasing effectiveness while minimizing the need for repeated hospital interventions.
How Zusduri Works
At its core, Zusduri is a mitomycin-based hydrogel. Mitomycin is a well-known chemotherapy agent used to treat various cancers, but the innovation lies in its delivery mechanism.
The gel is instilled into the bladder where it transforms into a semi-solid state at body temperature. This property helps it stay in place for extended periods, allowing the drug to work longer and more efficiently on bladder lining tissue.
Once the treatment duration is complete, the gel reverts to liquid form and is naturally excreted. This design allows for better retention of the drug within the bladder, limiting systemic exposure and potential side effects.
Patients typically receive the treatment once a week for six weeks in a urologist’s office—no surgery, no anesthesia, and no hospital stay required.
Clinical Success Behind the Approval
The FDA’s decision was based on data from a large, multi-center clinical trial involving patients with recurrent, low-grade NMIBC who had already undergone one or more prior surgical resections. These patients were seeking an alternative to yet another TURBT.
In the trial:
- Nearly 78% of patients achieved complete response within three months of completing the treatment course.
- Of those who responded, over 75% remained disease-free after one year.
- A significant number continued to remain recurrence-free even 18 months later.
The durability of response was a key factor that convinced regulators to approve the product, despite the absence of a traditional randomized control group. The need for a non-surgical option in this subset of patients, coupled with consistent clinical benefit, weighed heavily in the decision.
